<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672841</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00003161</org_study_id>
    <secondary_id>GA88517X</secondary_id>
    <nct_id>NCT00672841</nct_id>
  </id_info>
  <brief_title>β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients</brief_title>
  <official_title>Randomized Comparison of β-D-Glucan Surveillance With Preemptive Anidulafungin Versus Standard Care for the Management of Invasive Candidiasis in Surgical Intensive Care Unit Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective, open label assessment of β-D-glucan surveillance with
      preemptive anidulafungin therapy versus standard care for the prevention of invasive
      candidiasis in at-risk surgical intensive care unit (SICU) patients. Subjects will be
      stratified by APACHE II score and randomized in 3:1 fashion to either biweekly surveillance
      using the β-D-glucan assay or standard care. Subjects in the active monitoring arm will
      receive intravenous anidulafungin should the β-D-glucan exceed 60 pg/mL on a single
      determination. Subjects in the standard care arm will have biweekly blood draws for
      β-D-glucan, but the specimens will be batched and tested retrospectively. Antifungal use in
      the standard care arm is at the discretion of the treating physicians. The primary study
      end-points are the feasibility of a preemptive antifungal strategy in a SICU setting,
      β-D-glucan test characteristics, and the safety and tolerability of preemptive anidulafungin.
      Risks associated with study participation include the risks associated with blood draws,
      study drug related side effects, and the potential for loss of confidentiality.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients.</measure>
    <time_frame>Participants were followed until ICU discharge, an average of 17 days</time_frame>
    <description>Clinical utility was defined as β-D-glucan test performance. Biweekly βDG testing used a threshold of ≥ 60 pg/ml to indicate a positive test for invasive candidiasis. True and false positives, and true and false negatives were confirmed using a composite clinical definition of invasive candidiasis that combines physical symptom/signs and microbiology. Cases of proven/probable invasive fungal infection (IFI) were adjudicated by a single reviewer blinded to group assignment and BDG results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Preemptive Anidulafungin</measure>
    <time_frame>weekly until ICU discharge</time_frame>
    <description>reported as the Number of Adverse Events Possibly Related to Study Drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validate Gene Expression Signatures Predictive of IC</measure>
    <time_frame>Study Completion, an average of 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Proven or Probable Invasive Fungal Infection (IFI)</measure>
    <time_frame>Participants were followed until ICU discharge, an average of 17 days</time_frame>
    <description>Institution specific criteria were used to establish a diagnosis of proven or probable invasive candidiasis. Other IFIs were classified according to the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria. However, BDG results were not factored into the EORTC/MSG criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Invasive Candidiasis</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care/empiric therapy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active surveillance/ preemptive therapy group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preemptive Therapy with Anidulafungin</intervention_name>
    <description>Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Eraxis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empiric antifungal therapy based on physician discretion.</intervention_name>
    <description>Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Admission to the intensive care unit for ≥ 72 hours and expected to stay an additional
             48 hours

          -  IV access for administration of study drug

          -  Subject (or subject's legal representative) able to give written informed consent

        Exclusion Criteria:

          -  History of hypersensitivity or intolerance to echinocandin antifungals

          -  Liver function test (ALT, AST (aspartate aminotransferase), and/or total bilirubin)
             greater than 10 times the upper limits of normal (ULN)

          -  Pregnant or lactating women

          -  Treatment with systemic antifungal therapy within the preceding 7 days

          -  Documented invasive fungal infection at baseline/screening

          -  Life expectancy less than 2 days or moribund
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly E Hanson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara D Alexander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Perfect, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>February 21, 2012</results_first_submitted>
  <results_first_submitted_qc>March 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2013</results_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>candidemia</keyword>
  <keyword>invasive candidiasis</keyword>
  <keyword>preemptive antifungal therapy</keyword>
  <keyword>surveillance</keyword>
  <keyword>β-D-Glucan (BDG)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Anidulafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from June 2008 to December 2010 on three intensive care units.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Care, Empiric Treatment</title>
          <description>Standard care group. Empiric antifungal therapy initiated by physician preference for the treatment of suspected invasive candidiasis.</description>
        </group>
        <group group_id="P2">
          <title>Active Surveillance, Preemptive Therapy</title>
          <description>Active surveillance group. Preemptive therapy (i.e., intravenous anidulafungin 200mg on day one, then 100mg daily x 14 days) initiated in response to a positive 1,3-beta-D glucan test for the presumptive early treatment of invasive candidiasis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Comfort care</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>icteric specimens</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Antifungal therapy, negative glucan</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Care, Empiric Treatment</title>
          <description>Standard care group. Empiric antifungal therapy initiated by physician preference for the treatment of suspected invasive candidiasis.</description>
        </group>
        <group group_id="B2">
          <title>Active Surveillance, Preemptive Therapy</title>
          <description>Active surveillance group. Preemptive therapy initiated in response to a positive 1,3-beta-D glucan test for the presumptive early treatment of invasive candidiasis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="19"/>
                    <measurement group_id="B2" value="53" spread="20"/>
                    <measurement group_id="B3" value="53" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients.</title>
        <description>Clinical utility was defined as β-D-glucan test performance. Biweekly βDG testing used a threshold of ≥ 60 pg/ml to indicate a positive test for invasive candidiasis. True and false positives, and true and false negatives were confirmed using a composite clinical definition of invasive candidiasis that combines physical symptom/signs and microbiology. Cases of proven/probable invasive fungal infection (IFI) were adjudicated by a single reviewer blinded to group assignment and BDG results.</description>
        <time_frame>Participants were followed until ICU discharge, an average of 17 days</time_frame>
        <population>Two study subjects in the preemptive therapy arm were excluded from the analysis of assay sensitivity and specific due to icteric serum specimens.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance, Preemptive Therapy</title>
            <description>Active surveillance group. Preemptive therapy initiated in response to a positive 1,3-beta-D glucan test for the presumptive early treatment of invasive candidiasis</description>
          </group>
          <group group_id="O2">
            <title>Standard Care, Empiric Treatment</title>
            <description>Standard care group. Empiric antifungal therapy initiated by physician preference for the treatment of suspected invasive candidiasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients.</title>
          <description>Clinical utility was defined as β-D-glucan test performance. Biweekly βDG testing used a threshold of ≥ 60 pg/ml to indicate a positive test for invasive candidiasis. True and false positives, and true and false negatives were confirmed using a composite clinical definition of invasive candidiasis that combines physical symptom/signs and microbiology. Cases of proven/probable invasive fungal infection (IFI) were adjudicated by a single reviewer blinded to group assignment and BDG results.</description>
          <population>Two study subjects in the preemptive therapy arm were excluded from the analysis of assay sensitivity and specific due to icteric serum specimens.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>True BDG Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>True BDG Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>False BDG Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>False BGD Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Clinical sensitivity of the BDG test was calculated for both study groups combined</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Sensitivity</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Sensitivity [1] = (True positives [n=6]/ True positives + False negatives [n=6])</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Clinical specificity of the BDG test was calculated for the study groups combined</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Specificity</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Specificity [0.50]= True negatives [n=28]/ True negatives + False positives [56])</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Validate Gene Expression Signatures Predictive of IC</title>
        <time_frame>Study Completion, an average of 17 days</time_frame>
        <population>Data was not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance, Preemptive Therapy</title>
            <description>Active surveillance group. Preemptive therapy initiated in response to a positive 1,3-beta-D glucan test for the presumptive early treatment of invasive candidiasis</description>
          </group>
          <group group_id="O2">
            <title>Standard Care, Empiric Treatment</title>
            <description>Standard care group. Empiric antifungal therapy initiated by physician preference for the treatment of suspected invasive candidiasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Validate Gene Expression Signatures Predictive of IC</title>
          <population>Data was not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Proven or Probable Invasive Fungal Infection (IFI)</title>
        <description>Institution specific criteria were used to establish a diagnosis of proven or probable invasive candidiasis. Other IFIs were classified according to the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria. However, BDG results were not factored into the EORTC/MSG criteria.</description>
        <time_frame>Participants were followed until ICU discharge, an average of 17 days</time_frame>
        <population>4 subjects in the preemptive therapy were excluded from this analysis. These subjects were treated with empiric antifungal therapy despite repeatedly negative glucan results.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Care, Empiric Treatment</title>
            <description>Standard care group. Empiric antifungal therapy initiated by physician preference for the treatment of suspected invasive candidiasis.</description>
          </group>
          <group group_id="O2">
            <title>Active Surveillance, Preemptive Therapy</title>
            <description>Active surveillance group. Preemptive therapy initiated in response to a positive 1,3-beta-D glucan (BDG) test for the presumptive early treatment of invasive candidiasis</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Proven or Probable Invasive Fungal Infection (IFI)</title>
          <description>Institution specific criteria were used to establish a diagnosis of proven or probable invasive candidiasis. Other IFIs were classified according to the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria. However, BDG results were not factored into the EORTC/MSG criteria.</description>
          <population>4 subjects in the preemptive therapy were excluded from this analysis. These subjects were treated with empiric antifungal therapy despite repeatedly negative glucan results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The clinic sensitivity of the BDG test was calculated for both study groups combined</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Sensitivity = (true positives [n=6]/true positives + false negative [n=6])</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The clinical specificity of the BDG test was calculated for both study groups combined</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>52</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Specificity [0.52]= (True negatives [n=30]/True negatives + false positives [n=58])</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Preemptive Anidulafungin</title>
        <description>reported as the Number of Adverse Events Possibly Related to Study Drug</description>
        <time_frame>weekly until ICU discharge</time_frame>
        <population>Subjects receiving at least 1 dose of anidulafungin were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Care, Empiric Treatment</title>
            <description>Standard care group. Empiric antifungal therapy initiated by physician preference for the treatment of suspected invasive candidiasis.</description>
          </group>
          <group group_id="O2">
            <title>Active Surveillance, Preemptive Therapy</title>
            <description>Active surveillance group. Preemptive therapy initiated in response to a positive 1,3-beta-D glucan test for the presumptive early treatment of invasive candidiasis</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Preemptive Anidulafungin</title>
          <description>reported as the Number of Adverse Events Possibly Related to Study Drug</description>
          <population>Subjects receiving at least 1 dose of anidulafungin were assessed.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Care, Empiric Treatment</title>
          <description>Standard care group. Empiric antifungal therapy initiated by physician preference for the treatment of suspected invasive candidiasis.</description>
        </group>
        <group group_id="E2">
          <title>Active Surveillance, Preemptive Therapy</title>
          <description>Active surveillance group. Preemptive therapy initiated in response to a positive 1,3-beta-D glucan test for the presumptive early treatment of invasive candidiasis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver function tests</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study represents a 1st attempt at preemptive antifungal therapy based on the fungal biomarker 1,3-Beta-D-Glucan in the intensive care unit. Main limitation: the small number of subjects with proven/probable invasive candidiasis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kimberly E. Hanson, MD, MHS</name_or_title>
      <organization>University of Utah</organization>
      <phone>801.585.2867</phone>
      <email>kim.hanson@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

